MAGLE Stock Overview
Operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Magle Chemoswed Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 33.20 |
| 52 Week High | SEK 49.80 |
| 52 Week Low | SEK 24.40 |
| Beta | 0.57 |
| 1 Month Change | -1.19% |
| 3 Month Change | -13.54% |
| 1 Year Change | 30.71% |
| 3 Year Change | 22.96% |
| 5 Year Change | n/a |
| Change since IPO | 61.87% |
Recent News & Updates
Recent updates
Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Weaker Than They Seem
Nov 04
Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher
Jun 26Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet
Jun 19Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%
Mar 29Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings
Oct 05Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?
Jan 22Shareholder Returns
| MAGLE | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -2.2% |
| 1Y | 30.7% | 12.7% | 6.1% |
Return vs Industry: MAGLE exceeded the Swedish Life Sciences industry which returned 12.7% over the past year.
Return vs Market: MAGLE exceeded the Swedish Market which returned 6.1% over the past year.
Price Volatility
| MAGLE volatility | |
|---|---|
| MAGLE Average Weekly Movement | 7.6% |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: MAGLE has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: MAGLE's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 147 | Justin Pierce | www.maglechemoswed.com |
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company’s microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures.
Magle Chemoswed Holding AB (publ) Fundamentals Summary
| MAGLE fundamental statistics | |
|---|---|
| Market cap | SEK 610.94m |
| Earnings (TTM) | SEK 16.75m |
| Revenue (TTM) | SEK 209.21m |
36.5x
P/E Ratio2.9x
P/S RatioIs MAGLE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAGLE income statement (TTM) | |
|---|---|
| Revenue | SEK 209.21m |
| Cost of Revenue | SEK 25.74m |
| Gross Profit | SEK 183.48m |
| Other Expenses | SEK 166.73m |
| Earnings | SEK 16.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 87.70% |
| Net Profit Margin | 8.00% |
| Debt/Equity Ratio | 25.4% |
How did MAGLE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 22:00 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Magle Chemoswed Holding AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Sule | Redeye |